A further study found that breast cancer patients with the CYP2C8*3 allele achieved further clinically relevant outcomes using adjuvant paclitaxel (55 vs. 23%; OR: 3.92, 95% CI: 1.46–10.48, corrected P = 0.046) but a higher frequency of >grade 2 neurotoxicity was recorded (22 vs. 8%; OR: 3.13, 95% CI: 0.89–11.01, p = 0.075). The gene discussed is CYP2C8; the disease is breast cancer.